Geron Corporation (GERN): Price and Financial Metrics
GERN Stock Summary
- With a price/sales ratio of 1,477.65, Geron Corp has a higher such ratio than 99.4% of stocks in our set.
- With a year-over-year growth in debt of 8,404.01%, Geron Corp's debt growth rate surpasses 99.56% of about US stocks.
- Revenue growth over the past 12 months for Geron Corp comes in at -43.68%, a number that bests just 7.59% of the US stocks we're tracking.
- Stocks that are quantitatively similar to GERN, based on their financial statements, market capitalization, and price volatility, are MRSN, BBIO, ATHX, CRNX, and CRDF.
- Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to www.geron.com.
GERN Stock Price Chart Interactive Chart >
GERN Price/Volume Stats
|Current price||$1.77||52-week high||$2.40|
|Prev. close||$1.78||52-week low||$0.75|
|Day high||$1.81||Avg. volume||3,981,336|
|50-day MA||$1.78||Dividend yield||N/A|
|200-day MA||$1.83||Market Cap||547.98M|
Geron Corporation (GERN) Company Bio
Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
GERN Latest News Stream
|Loading, please wait...|
GERN Latest Social Stream
View Full GERN Social Stream
Latest GERN News From Around the Web
Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. A replay of the webcast will be available on
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Tech news site Protocol has hired Wall Street Journal reporter Tomio Geron to cover financial technology. He has been writing about technology, venture capital and startups for WSJ Pro Venture Capital and The Wall Street Journal…
GERN Price Returns
Continue Researching GERNWant to do more research on Geron Corp's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!